Nutrition 21 Signs Licensing Agreement With Provita to Market Coldizin(TM) for Upper Respiratory Health Products

PURCHASE, NY--(Marketwire - November 4, 2010) -  Nutrition 21, Inc. (OTCBB: NXXI), the developer and marketer of clinically substantiated ingredients for dietary supplements, foods and beverages, and animal nutrition, today announced that it entered into a binding agreement with Provita Development ApS of Denmark ("Provita") that grants the Company an exclusive license in the United States and Canada for Coldizin™, an ingredient combination, patented in the US and Europe, for enhancing upper-respiratory health. A patent is pending in Canada. The exclusive license allows Nutrition 21 to expand its product portfolio with a novel, clinically substantiated ingredient for the $4.5 billion U.S. cough and cold category.

"Coldizin is a clinically substantiated product that shows significant results in helping people deal with upper respiratory symptoms. Its innovative blend of the bioflavonoid troxerutin and zinc provides an option for either the dietary supplement or homeopathic segments," stated William J. Levi, Vice President Ingredients and Special Markets.

Carsten Waern, CEO and chairman of Provita said, "We are excited to have a professional partner in Nutrition 21, who understands the North American marketplace and is a well-established, credible player in the industry. They have an excellent history of selling and marketing value-added and clinically substantiated ingredients. We look forward to a mutually successful, long-term partnership."

Michael Zeher, Nutrition21's president and chief executive officer, stated, "This new product fits nicely into our expansion strategy by providing us with an innovative and product patented for use in the very significant cold and cough market segment. We are delighted to have Provita as a partner."

About Nutrition 21
Nutrition 21, Inc. (OTCBB: NXXI), headquartered in Purchase, NY, is a nutritional bioscience company and holds over 60 issued and pending patents for dietary supplement ingredients, including chromium picolinate, and combinations of chromium compounds with other ingredients. Its products are sold to leading dietary supplement, functional food and beverage, and animal nutrition manufacturers. For more information please visit http://www.nutrition21.com.

Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2010. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

Contact Information:

Company Contact:
William J. Levi
Vice President
914-701-4500

Investor Contact:
Alan Kirschbaum
Chief Financial Officer
914-701-4500